Acadia Pharmaceuticals

Performance

About Acadia Pharmaceuticals

Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for underserved neurological disorders and rare diseases. The company has FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome and maintains a robust pipeline addressing conditions such as Alzheimer's disease psychosis and Lewy body dementia psychosis, with efforts spanning research, development, and patient support. Headquartered in the United States with a global reach, Acadia emphasizes patient-centric approaches, partnerships, and responsible innovation to bring meaningful improvements to patients and families affected by complex neurological conditions.